- GLPG-1690 USP/EP/BP
-
- $1.10 / 1g
-
2021-08-19
- CAS:1628260-79-6
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
|
| | GLPG-1690 Basic information |
| Product Name: | GLPG-1690 | | Synonyms: | GLPG-1690;5-Thiazolecarbonitrile, 2-[[2-ethyl-6-[4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-1-piperazinyl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)-;CS-2644;GLPG 1690;GLPG1690;GLPG-1690; GLPG 1690; GLPG1690; ZIRITAXESTAT.;GLPG-1690 USP/EP/BP;2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;ziritaxestat | | CAS: | 1628260-79-6 | | MF: | C30H33FN8O2S | | MW: | 588.7 | | EINECS: | | | Product Categories: | APIS;API | | Mol File: | 1628260-79-6.mol |  |
| | GLPG-1690 Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:70.84(Max Conc. mg/mL);120.32(Max Conc. mM)
Ethanol:4.0(Max Conc. mg/mL);6.79(Max Conc. mM) | | form | A crystalline solid | | pka | 13.72±0.20(Predicted) |
| | GLPG-1690 Usage And Synthesis |
| Uses | GLPG1690 is a selective autotaxin inhibitor discovered by Galapagos, with potential application in idiopathic pulmonary disease (IPF). In a Phase 1 study in healthy human volunteers, GLPG1690 demonstrated favorable safety and tolerability, as well as a strong pharmacodynamic signal implying target engagement. |
| | GLPG-1690 Preparation Products And Raw materials |
|